Cargando…

Novel specific activity-based probes validate KLK proteases as druggable targets

Detalles Bibliográficos
Autores principales:	Sotiropoulou, Georgia, Zingkou, Eleni, Pampalakis, Georgios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176256/ https://www.ncbi.nlm.nih.gov/pubmed/35652924 http://dx.doi.org/10.1080/15384047.2022.2074775

Ejemplares similares

Biochemical pathways mediated by KLK6 protease in breast cancer
por: Pampalakis, Georgios, et al.
Publicado: (2019)

Activity-Based Probes for Proteases Pave the Way to Theranostic Applications
por: Sotiropoulou, Georgia, et al.
Publicado: (2022)

The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway
por: Pampalakis, Georgios, et al.
Publicado: (2013)

Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6
por: Sotiropoulou, Georgia, et al.
Publicado: (2012)

Kallikreins emerge as new regulators of viral infections
por: Pampalakis, Georgios, et al.
Publicado: (2021)

A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis
por: Pampalakis, Georgios, et al.
Publicado: (2022)

KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome
por: Furio, Laetitia, et al.
Publicado: (2015)

KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species
por: Pampalakis, Georgios, et al.
Publicado: (2016)

Birth-and-Death of KLK3 and KLK2 in Primates: Evolution Driven by Reproductive Biology
por: Marques, Patrícia Isabel, et al.
Publicado: (2012)

A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell Invasion
por: Zhang, Leran, et al.
Publicado: (2022)

Evolutionary History of Tissue Kallikreins
por: Pavlopoulou, Athanasia, et al.
Publicado: (2010)

Genetically-modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)-based targeted therapy (Review)
por: Devetzi, Marina, et al.
Publicado: (2018)

Netrin-1 overexpression is predictive of ovarian malignancies
por: Papanastasiou, Anastasios D., et al.
Publicado: (2011)

Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer - a new pool of biomarkers
por: Pampalakis, Georgios, et al.
Publicado: (2015)

KLK-targeted Therapies for Prostate Cancer
por: Hannu, Koistinen, et al.
Publicado: (2014)

Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
por: Tamir, Ayala, et al.
Publicado: (2014)

MMP20, KLK4, and MMP20/KLK4 double null mice define roles for matrix proteases during dental enamel formation
por: Hu, Yuanyuan, et al.
Publicado: (2015)

Evolutionary Survey of Druggable Protein Targets with Respect to Their Subcellular Localizations
por: Wang, Xiaotong, et al.
Publicado: (2013)

Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein
por: Chen, Hwudaurw, et al.
Publicado: (2019)

A comprehensive resequence analysis of the KLK15–KLK3–KLK2 locus on chromosome 19q13.33
por: Parikh, Hemang, et al.
Publicado: (2009)

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
por: White, N M A, et al.
Publicado: (2009)

Prediction of Druggable Allosteric Sites of Undruggable Multidrug Resistance Efflux Pump P. Gingivalis Proteins
por: Yadalam, Pradeep Kumar, et al.
Publicado: (2023)

A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer
por: Lovell, Scott, et al.
Publicado: (2021)

KLK4T2 Is a Hormonally Regulated Transcript from the KLK4 Locus
por: Lundwall, Åke, et al.
Publicado: (2021)

Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling
por: Porta, Exequiel O. J., et al.
Publicado: (2022)

Novel Biomarkers and Druggable Targets in Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Novel inhibitors and activity-based probes targeting serine proteases
por: Ferguson, Timothy E. G., et al.
Publicado: (2022)

Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma
por: Rückert, F, et al.
Publicado: (2008)

KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype
por: Kasparek, Petr, et al.
Publicado: (2017)

Novel KLK4 Mutations Cause Hypomaturation Amelogenesis Imperfecta
por: Lee, Yejin, et al.
Publicado: (2022)

Functional proteomic profiling reveals KLK13 and TMPRSS11D as active proteases in the lower female reproductive tract
por: Muytjens, Carla M.J., et al.
Publicado: (2018)

KLK3 in the Regulation of Angiogenesis—Tumorigenic or Not?
por: Koistinen, Hannu, et al.
Publicado: (2021)

Monobodies as tool biologics for accelerating target validation and druggable site discovery
por: Akkapeddi, Padma, et al.
Publicado: (2021)

Autocatalytic activation of a malarial egress protease is druggable and requires a protein cofactor
por: Tan, Michele S Y, et al.
Publicado: (2021)

Novel technique in placement of transesophageal echocardiography probe in neurosurgical procedures
por: Gopalakrishna, Kadarapura Nanjundaiah, et al.
Publicado: (2014)

Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility
por: Gupta, Nishi, et al.
Publicado: (2017)

A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression
por: Liu, Yueyang, et al.
Publicado: (2022)

Drugging the undruggable: activity-based protein profiling offers opportunities for targeting the KLK activome
por: Lee, Kristi Y., et al.
Publicado: (2022)

Phosphinate esters as novel warheads for activity-based probes targeting serine proteases
por: Kahler, Jan Pascal, et al.
Publicado: (2021)

Novel Inhibitors and Activity-Based Probes Targeting Trypsin-Like Serine Proteases
por: Ferguson, Timothy E. G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u7sqi3mm36sqkr8cg74ir7f386